Sanofi: ASCO: Sarclisa is first anti-CD38 to significantly i

ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 Sarclisa, in combination

Related Keywords

Paris , France General , France , United States , French , American , Tarik Elgoutni , Thomas Kudsk Larsen , Felix Lauscher , Keita Browne , Evan Berland , Peterc Adamson , Sandrine Guendoul , Timothy Gilbert , Thierry Facon , Nathalie Pham , French Academy Of Medicine , Drug Administration , American Society Of Clinical Oncology , Lille University Hospital , Global Development Head , European Hematology Association , World Health Organization , Congress On , European Union , Euronext , Department Of Haematology , Nasdaq , American Society , Clinical Oncology , New England Journal , French Academy , Development Head , Newly Diagnosed Multiple , Priority Review , Biologics License Application , Annual Congress , Nonproprietary Naming , Biological Products Guidance , Kudsk Larsen , Private Securities Litigation Reform Act , Statement Regarding Forward Looking , Accessed September , Accessed March , Ihr Portfolio ,